Kenai Therapeutics (Kenai) is a biotechnology company pioneering next generation approaches to cure neurological conditions. The Company utilizes induced pluripotent stem cell (iPSC) technology, a Nobel Prize-winning breakthrough that enables scientists to manufacture any human cell, to generate Kenai’s off-the-shelf neuron replacement therapeutics. By focusing on an iPSC technology platform, and forging partnerships with global leaders in surgical delivery and clinical development, Kenai is dedicated to advancing a best-in-class pipeline targeting neurological conditions. Kenai Therapeutics closed an $82 million Series A financing in 2024, co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures. For additional information, please visit: www.kenaitx.com.
Company Details
- Employees
- 26
- Address
- San Diego, California, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.kenaitx.com
- Keywords
- Manager jobs.
- HQ
- San Diego, California
Kenai Therapeutics Questions
Kenai Therapeutics's website is http://www.kenaitx.com
Kenai Therapeutics's LinkedIn profile is https://www.linkedin.com/company/kenaitx
Kenai Therapeutics has
26 employees.
View email and phone details for 26
employees at Kenai Therapeutics.
Kenai Therapeutics's industry is
Biotechnology Research
Kenai Therapeutics's top competitors are
Tenvie Therapeutics,
Biosapien,
Attovia Therapeutics,
Shinobi Therapeutics,
Curve Biosciences,
Light Horse Therapeutics,
Avenzo Therapeutics,
Arda Therapeutics,
Moonwalk Biosciences,
Siteone Therapeutics, Inc..
Kenai Therapeutics's categories are Biotechnology Research
